Phase 1 Study of 18F3F4AP PET Imaging for Demyelination in Healthy Adults and Those with Neurological Conditions

What this Trial Is About

Researchers are studying the pharmacokinetics of 18F3F4AP, a tracer used in PET scans, in healthy adults and people with demyelinating disorders such as mild cognitive impairment MCI, Alzheimers Disease, Multiple Sclerosis, Spinal Cord Injury, and Spinal Radiculopathy. This Phase 1 trial aims to better understand how this tracer distributes in the body and how it relates to disease markers like demyelination, tau, and amyloid burdens. Participants will undergo up to three PET scan sessions using three different tracers 11CPIB, 18FMK6240, and 18F3F4AP. The study groups include healthy controls and people diagnosed with the listed demyelinating conditions. Each group will have multiple PET scans to capture various imaging measures related to brain pathology and disease progression. During the study, participants will have brain imaging sessions to assess tracer distribution, brain atrophy, cerebrovascular burden, and white matter lesions. Researchers will evaluate multiple biomarkers and imaging outcomes over five years. The study involves no randomization or masking, and participants will be monitored for safety and imaging results throughout the trial.

Exploring the Utility of [18F]3F4AP for Demyelination Imaging